Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 431

1.

Chronic phase of ETV6-ABL1 positive CML responds to imatinib.

Kawamata N, Dashti A, Lu D, Miller B, Koeffler HP, Schreck R, Moore S, Ogawa S.

Genes Chromosomes Cancer. 2008 Oct;47(10):919-21. doi: 10.1002/gcc.20593. No abstract available.

PMID:
18615681
2.

Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate.

Barbouti A, Ahlgren T, Johansson B, Höglund M, Lassen C, Turesson I, Mitelman F, Fioretos T.

Br J Haematol. 2003 Jul;122(1):85-93.

PMID:
12823349
3.

BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration.

Campbell LJ, Patsouris C, Rayeroux KC, Somana K, Januszewicz EH, Szer J.

Cancer Genet Cytogenet. 2002 Nov;139(1):30-3.

PMID:
12547154
4.

Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts.

Lee JJ, Kim HJ, Kim YJ, Lee S, Hwang JY, Kim YL, Kim DW.

Leukemia. 2004 Sep;18(9):1539-40. No abstract available.

PMID:
15284852
5.

Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.

Gozzetti A, Bocchia M, Calabrese S, Pirrotta MT, Crupi R, Raspadori D, Lauria F.

Acta Haematol. 2007;117(4):236-7. Epub 2007 Feb 14. No abstract available.

PMID:
17308370
6.

Hematological and molecular response evaluation of CML patients on imatinib.

Gupta A, Prasad K.

J Assoc Physicians India. 2007 Feb;55:109-13.

PMID:
17571739
7.

e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia.

Roti G, La Starza R, Gorello P, Gottardi E, Crescenzi B, Martelli MF, Mecucci C.

Haematologica. 2005 Aug;90(8):1139-41.

8.

[Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients].

Qin YZ, Liu YR, Li JL, Ruan GR, Zhu HH, Jiang Q, Fu JY, Lu Y, Chang Y, Li LD, Huang XJ, Chen SS, Qiu JY.

Zhonghua Yi Xue Za Zhi. 2005 Nov 30;85(45):3186-9. Chinese.

PMID:
16405837
9.

Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase.

Moravcová J, Zmeková V, Klamová H, Voglová J, Faber E, Michalová K, Rabasová J, Jarosová M.

Leuk Res. 2004 Apr;28(4):415-9.

PMID:
15109543
10.

Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy--a fluorescence in-situ hybridization study.

Thiele J, Kvasnicka HM, Varus E, Ollig E, Schmitt-Graeff A, Staib P, Griesshammer M.

Leuk Lymphoma. 2004 Aug;45(8):1627-31.

PMID:
15370216
11.

Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.

Arancibia AM, Bendit I, Epelman S.

Pediatr Blood Cancer. 2008 May;50(5):1078. No abstract available.

PMID:
18085674
12.

Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib.

Breccia M, Santopietro M, Cannella L, Federico V, Loglisci G, Serrao A, Petrucci L, Salaroli A, Nanni M, De Propris MS, Diverio D, Alimena G.

Leuk Res. 2011 Jun;35(6):e91-2. doi: 10.1016/j.leukres.2011.01.026. Epub 2011 Feb 11. No abstract available.

PMID:
21316103
13.

Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.

Agarwal MB.

J Assoc Physicians India. 2007 Feb;55:99-100. No abstract available.

PMID:
17571737
14.
15.

Resistance and relapse with imatinib in CML: causes and consequences.

Deininger M.

J Natl Compr Canc Netw. 2008 Mar;6 Suppl 2:S11-S21. Review.

PMID:
18397677
16.

Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.

Chien JH, Tang JL, Chen RL, Li CC, Lee CP.

Leuk Res. 2008 Nov;32(11):1724-34. doi: 10.1016/j.leukres.2008.04.023. Epub 2008 Jul 7.

PMID:
18603297
17.

New-age drug meets resistance.

McCormick F.

Nature. 2001 Jul 19;412(6844):281-2. No abstract available.

PMID:
11460142
18.

Imatinib and chronic-phase leukemias.

Boros LG, Lee WN, Cascante M.

N Engl J Med. 2002 Jul 4;347(1):67-8. No abstract available.

19.

Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status.

Alimena G, Breccia M, Mancini M, Diverio D, Nanni M, De Propris MS, Cimino G, Pane F, Mandelli F.

Leukemia. 2005 Feb;19(2):287-9. No abstract available.

PMID:
15538403
20.

Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib.

Agirre X, Román-Gómez J, Vázquez I, Jiménez-Velasco A, Larráyoz MJ, Lahortiga I, Andreu EJ, Márquez J, Beltrán de Heredia JM, Odero MD, Prósper F, Calasanz MJ.

Cancer Genet Cytogenet. 2005 Jul 1;160(1):22-6.

PMID:
15949566

Supplemental Content

Support Center